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PCV14
USING THE GENERAL PRACTICE RESEARCH 
DATABASE TO GENERATE AN “AT RISK 
REGISTER” FOR A PRIMARY CARE STROKE 
PREVENTION PROGRAM
Chapman SR, Heatlie HF, Frischer M, Bashford J
Department of Medicines Management, Keele University, 
Staffordshire, UK
OBJECTIVE: To create a register of patients in the West
Midlands from the General Practice Research Database
(GPRD) who may be eligible for primary prevention
treatment of stroke with an ACE inhibitor according to
the inclusion and exclusion criteria of the HOPE study
METHODS: A retrospective database analysis for pa-
tients registered on GPRD during 1998 THE GPRD is a
representative sample of approximately 5% of the popu-
lation. Participating general practitioners enter all pre-
scriptions, significant morbidity and consultation out-
comes. Patients over 54 at January 1998 were selected,
then those at high risk of cardiovascular events according
to the HOPE study diagnostic inclusion criteria. Patients
were categorized as either treated or not treated. Treated
patients were further classified as either having received
an ‘ACE inhibitor’ or ‘other antihypertensive’ treatment.
Patients receiving an ACE inhibitor prescriptions as well
as ‘other antihypertensive’ treatment were classified as
ACE inhibitor patients. ACE inhibitor patients were then
sub-classified into higher and lower dose ACE inhibitors.
Higher dose ACE treatment was defined as patients pre-
scribed ACE inhibitors at or greater than the World
Health Organization (WHO) defined daily dose (DDD).
Counts were made for patients receiving ramipril as op-
posed to another ACE inhibitor. RESULTS: The GPRD
had 214,401 patients registered during 1998. 66,548 pa-
tients were over 54 years old, 10,983 (16.5%) were clas-
sified as at risk of cardiovascular events. 3,635 (33%) at
risk patients were untreated. 7,348 patients were treated;
of whom 2,156 were receiving some form of ACE inhibi-
tor therapy. 1,700 patients were on high dose ACE inhib-
itor therapy, of which 284 had been prescribed ramipril.
CONCLUSION: THE GPRD can be used to create a reg-
ister of at risk patients in primary care. This gives a mea-
sure of potential workload, and could populate a phar-
macoeconomic study on the cost of implementing the
HOPE recommendations.
PCV15
ANTI-HYPERTENSIVE AGENTS AND THE
RISK OF HIP OR WRIST FRACTURES IN
AN OTHERWISE HEALTHY
COMMUNITY POPULATION
Läer C, LeLorier J
Centre de Recherche, Hôtel-Dieu du Centre hospitalier de 
l’Université de Montréal, Montréal, QC, Canada
OBJECTIVE: Psychotropic agents are an established risk
factor for hip fractures. These agents induce drowsiness,
sleepiness, and orthostatic hypotension. Orthostatic hy-
potension is a major side effect of anti-hypertensive agents
(AH). Conflicting results have been published with respect
to AH-agents and the risk of hip fractures, with relative
risk estimates ranging from 0.46 (CI 95%: 0.13–1.55) to
11.8 (CI 95%: 6.11–22.69). The objective is to assess the
risk of hip or wrist fractures in an otherwise healthy hy-
pertensive elderly community population. METHOD: A
nested case-control study of AH-users older than 65
years at the first dispensation of an AH (excluding ni-
trates and high dose furosemide) was conducted on a
10% random sample from January 1st 1987 to Decem-
ber 31st 1994, and a 20% sample of all AH-users
between August 1st 1992 and August 30th 1997 of
the “Régie de l’assurance maladie du Québec” database
(RAMQ). Community cases and controls were selected at
their first hospitalized index event. Both groups had
taken AH-medication and only one antibiotic for a maxi-
mum of 14 days in the 92 days preceding the index day.
Cases were subjects with hip or wrist fractures, and con-
trols had pneumonia, cellulitis, diverticulitis, pyelone-
phritis or acute appendicitis. Conditional logistic regres-
sion was performed. RESULTS: From our AH-cohort of
160,940 members, 254 cases and 897 controls were se-
lected. The overall adjusted odds-ratio was 0.87 (CI 95%:
0.66–1.17). CONCLUSION: Modern anti-hypertensive
therapy does not increase the risk of fractures of the hip
or wrist in an otherwise healthy elderly community popu-
lation.
PCV16
COST-EFFECTIVENESS OF
LOW-MOLECULAR WEIGHT HEPARIN
VERSUS ORAL ANTICOAGULANTS FOR 
SECONDARY PROPHYLAXIS OF
VENOUS THROMBOEMBOLISM
Marchetti M1, Pistorio A2, Barosi G1
1Laboratory of Medical Informatics, IRCCS Policlinico S.Matteo, 
Pavia, Italy; 2Epidemiology Center IRCCS Policlinico S.Matteo, 
Pavia, Italy
OBJECTIVE: Recent evidence suggests that low molecu-
lar weight heparin (LMWH) can be used as an alternative
to oral anticoagulants in the prevention of recurrences af-
ter deep venous thrombosis (DVT). Our objective was to
examine the clinical, economic and policy implications of
LMWH instead of oral anticoagulants as secondary pro-
phylaxis for DVT. METHODS: Fixed-effect model was
used to conduct a meta-analysis of data about safety and
effectiveness of LMWH from 4 trials. A decision tree was
constructed using published data to simulate the out-
comes and cost of care of patients receiving secondary
prophylaxis with either LMWH or oral anticoagulants
after a first episode of DVT. RESULTS: Meta-analysis
showed that the OR for bleeding, DVT and pulmonary
embolism were respectively 0.402 (0.153–1.057), 0.665
(0.22–2.013) and 0.462 (0.075–2.825). None of the three
OR was significant, however, the upper limit of the 95%
